Melanoma is the third most common cancer and every six hours, one Australian dies from melanoma.
2022
Immunotherapy combination enables melanoma survivor to sail through retirement
A cancer diagnosis is never good news, but Paul McKinney knows that his stage III melanoma diagnosis at least came at a “good” time in terms of progress in treating the disease
Preoperative immune-therapy combination shows promise in skin cancer
Treatment with the drugs relatlimab and nivolumab before the surgical removal of a type of cancer called melanoma resulted in tumours becoming inviable in 57% of individuals, and no severe adverse effects were observed.
New Checkpoint Inhibitor Immunotherapy Treatment for Advanced Melanoma Shows Promise
When Nancy Schroeder found out her melanoma had spread to her lymph nodes four years after she’d had surgery from a local dermatologist near her home in Florida, she knew she needed to go to Memorial Sloan Kettering Cancer Center (MSK) to benefit from the latest research and newest therapies.